ArticleBlood cancer journal2018
Long-term efficacy and safety of dasatinib in patients with chronic myeloid leukemia in accelerated phase who are resistant to or intolerant of imatinib.
Article in Blood cancer journal, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed, 30 citations in OpenAlex.
- Management of tyrosine kinase inhibitors and donor lymphocyte infusions post transplantation for chronic myeloid leukemia: a survey of contemporary practice on behalf of the chronic malignancies working party of the EBMT.Bone marrow transplantation · 2026Article
- Olverembatinib in accelerated-phase chronic myeloid leukemia: efficacy and safety evaluation.Haematologica · 2026Article
- Translating cellular senescence research into clinical practice for metabolic disease.Nature reviews. Endocrinology · 2026Review
- Intermittent hypobaric pressure induces selective senescent cell death and alleviates age-related osteoporosis.Nature biomedical engineering · 2026Article
- The Potential of Polyphenols in Modulating the Cellular Senescence Process: Implications and Mechanism of Action.Pharmaceuticals (Basel, Switzerland) · 2025Review
- The Impact of Pretransplant Use of Tyrosine Kinase Inhibitors on Allogeneic Stem Cell Transplantation in Patients with Chronic Myeloid Leukemia - A Single-institution Retrospective Study.Internal medicine (Tokyo, Japan) · 2024Article
- Cardiovascular Adverse Events of Tyrosine Kinase Inhibitors in Chronic Myeloid Leukemia: Clinical Relevance, Impact on Outcome, Preventive Measures and Treatment Strategies.Current treatment options in oncology · 2023Review
- An Update on the Management of Advanced Phase Chronic Myeloid Leukemia.Current hematologic malignancy reports · 2023Review
- Ruscogenin ameliorates dasatinib-induced intestinal barrier dysfunction via ErbB4/YAP and ROCK/MLC pathways.Journal of natural medicines · 2023Article
- Cellular senescence and senolytics: the path to the clinic.Nature medicine · 2022Review
- Dasatinib-Induced Bilateral Pleural Effusions.Cureus · 2022Article
- A one-pot electrochemical synthesis of 2-aminothiazoles from active methylene ketones and thioureas mediated by NHBeilstein journal of organic chemistry · 2022Article
- Peruvoside is a novel Src inhibitor that suppresses NSCLC cell growth and motility by downregulating multiple Src-EGFR-related pathways.American journal of cancer research · 2022Article
- Antineoplastic kinase inhibitors: A new class of potent anti-amoebic compounds.PLoS neglected tropical diseases · 2021Article
- Impact of the Breakpoint Region on the Leukemogenic Potential and the TKI Responsiveness of AtypicalFrontiers in pharmacology · 2021Article
- Exosomes from Bone Marrow Microenvironment-Derived Mesenchymal Stem Cells Affect CML Cells Growth and Promote Drug Resistance to Tyrosine Kinase Inhibitors.Stem cells international · 2020Article
- YQFM Alleviates Side Effects Caused by Dasatinib through the ROCK/MLC Pathway in Mice.Evidence-based complementary and alternative medicine : eCAM · 2020Article
- Management of Chronic Myeloid Leukemia in Advanced Phase.Frontiers in oncology · 2019Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors at 11 institutions in 7 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
PubMed holds no abstract for this paper.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.